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Abstract:

Previous work has shown that elderly women with chronic or infectious disease are at an
especially high risk for mental health disorders such as depression and anxiety 1. Although,
Nontuberculous mycobacterium (NTM) is a common lung disease in Oregon, little research has
been published on fundamental epidemiological measures such as prevalence, or incidence,
populations risks, and disease comorbidities 2 3 4. The objective of the study is to build a
rationale for screening for anxiety and depression in NTM patients through a review of current
literature of other lung diseases. Additionally, this project includes a chart review that shows the
proportion of patients with NTM who lack history of mental health diagnosis or medication
prescription, but have high scores on the Patient Health Questionnaire (PHQ-8) and/or
Generalized Anxiety Disorder (GAD-7), reflecting potentially significant symptomology of
either depression, anxiety, or both. A cutoff score for “positive” vs. “negative” presence of each
disorder was established, based on prior studies using these scales. Questionnaire data have been
accumulated on patients in the study. These data were gathered, originally, for a larger biobank
study by OHSU’s Center for Infectious Disease team. In addition to the screening results, data
regarding the patients’ anxiety and/or depression diagnosis history and psychotherapeutic
medication prescription history has been included in analysis. This has been done through a chart
review of the patients’ electronic medical records using the Epic system. Statistical analysis
using a chi-square has helped ascertain if the prevalence of patients who show symptoms, but no
intervention is significantly higher than in those who do not. For both depression and anxiety
there is a statistically significant relationship (p<0.05 and p<0.001 respectively) between

screening score and the presence of a diagnosis/medication. Most participants who screened
positive had both a diagnosis and took medications or they had neither. With these data I provide
a recommendation that once patients are found positive for NTM, providers should screen for
both depression and anxiety regardless of mental health history.
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Background/Literature Review

What is Nontuberculous mycobacterium:

Nontuberculous mycobacterium (NTM) is a non-contagious, chronic, pulmonary lung
condition. NTM is most commonly caused by the pathogenic complex Mycobacterium aviumintracellulare. However, dozens of bacteria that result in NTM have been documented. The
mechanism of disease onset is currently unknown, although research has linked infection to
vaporized water and airborne soil 5.
Similar to tuberculosis (TB), chronic obstructive pulmonary disease (COPD), and cystic
fibrosis (CF), the symptoms of NTM include shortness of breath (SOB), excessive coughing,
fever and/or fatigue 5. Although this disease affects mostly older people, for years patients are
often misdiagnosed with other lung conditions such as asthma. In order to correctly diagnose this
disease, two positive sputum samples or one bronchoscopy and a chest CT is needed. The
disease displays itself differently among patients, which is part of the reason why it is often
misdiagnosed. Some patients are asymptomatic and others, due to severe comorbidities and other
clinical issues, may require oxygen. Another interesting differentiation between patients is that
some patients may clear or contain the infection without further disease progression. For other
patients, the disease will progress typically for several years causing chronic airway infection,
destruction of lung tissue, shortness of breath, fatigue, decreased quality of life, and in some
cases death. Treatment of this disease requires an antibiotic regime of 3-5 drugs for typically 1824 months 5. Multiple drugs are required to control the symptoms and prevent disease spread, but
the treatments are rarely curative. Additionally, the antibiotics often have irreversible negative
side effects like the risk of hearing and vision loss. Finally, another major barrier to treating

NTM is the high rate of comorbidities with other diseases such as COPD, bronchiectasis, and CF
5

.
Due to minimal availability of epidemiological data and literature on NTM, few sources

have obtained reports of the average age of NTM diagnosis, which is estimated to be around 69
years 2 6. Women have been found to be affected disproportionately more often than men; they
comprise approximately 56 % of patients with NTM 2. The prevalence of NTM in 2006 was
twenty per one-hundred thousand 7. Although, the prevalence was low, the incidence has been
steadily increasing over the last decade 2.

Anxiety and Depression in the General Population:

The CDC defines depressive disorder as a prolonged feeling of sadness that interferes
with normal functioning of life 8. The NIH defines anxiety disorder as prolonged feeling of
uneasiness or worry that, like depression disorder, interferes with normal functioning of life 9.
According to the Anxiety and Depression Association of America, the prevalence of Major
Depressive Disorder and Generalized Anxiety Disorder are 6.7% and 3.1% respectively 10.
Healthy geriatric patients have been shown to have a prevalence of depression 1-4%. Women in
the elderly population are found to have depression twice as often compared to elderly men 11.
One study also found that healthy geriatric patients have also shown a prevalence anxiety of
4.6%, with only 36% being treated for it 11. Anxiety, in elderly populations, have a prevalence of
comorbidity with depression to be 38.6 %, which means it is not uncommon for patients to
experience both 12.Overall, with regards to risk, elderly patients who are single, younger, female,
and low income are more likely to experience anxiety and depression symptoms 12 13.One of the

reasons why mental health is studied in this population is that affective disorders like depression
and anxiety have been shown to be major drivers of patient’s health and quality of life 14.
Treatment for depression, as well as anxiety, is mainly pharmacotherapy and psychotherapy.
Other forms of therapy like exercise, yoga, and music can also reduce anxiety and depression
symptoms 15 16.

What started the conversation of mental health in NTM patients:

In 2015, the Center of Infectious Disease team (CIDS) at OHSU gathered together
clinicians, patients, and providers from all around the state. They spent an entire day discussing
the lack of research in NTM research and clinical care. One of the topics that was brought up
was the need for assistance in lessening the impact of mental health for patients with NTM 17.
This had kickstarted the conversation surrounding mental health for this patient population and
exemplified the need for research. Currently, there appears to be little or no research being done
to determine the prevalence and impact of mental health disturbances in patients with NTM. This
is the case, although depression and/or anxiety in bronchiectasis, TB, COPD, and CF are widely
studied. To show the importance of studying mental health in this population, other lung disease
research will be used as a baseline of information. The three lung diseases most like NTM are
chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and tuberculosis (TB).
COPD is a chronic lung condition that causes obstructed airflow. CF is a chronic genetic disorder
that allows thick mucus to get clogged in the patient’s airways. TB, on the other hand, is the
most similar lung condition to NTM, because it is a chronic infectious disease. TB and NTM are
also similar with regards to patient clinical symptoms and signs, and chest radiograph results 18.

Depression and Anxiety in Lung Disease Populations:

Chronic disease, as well as lung disease populations have high rates of anxiety and
depression. Depression in TB patients have been shown to be present in up to 70 % of
ambulatory populations and 80 % in hospitalized populations 14. It’s also been found that
depression and anxiety in TB patients has a prevalence of 43 % and 41 % respectively, with a
comorbidity of both to be 40 % 19. One study found that one in four COPD patients experience
significant depression symptoms 20. COPD patients are ten times more likely to experience
anxiety symptoms or panic attacks compared to the general population 20. Anxiety has shown to
have a prevalence of about 40% in COPD patients 20. For patients with interstitial lung disease,
the prevalence of depression is 21 % 21. Anxiety, on the other hand has been observed in 31% of
patients with interstitial lung disease 22. Looking at CF patients, in one study 19 % have shown
depressive symptoms and 32 % have shown anxiety symptoms. Overall, the symptom elevations
were 2–3 times those of community samples 23. With increasing symptom severity, the number
of symptoms, and the amount of medications, comes an increasing rate of depression and anxiety
20 21

. It is unclear what happens first, the lung disease symptoms severity or the depression, but

with interstitial lung it is argued that it is actually health related quality of life, dyspnea, and lack
of physical activity that leads to the mental disorder symptoms 20.
Knowing that lung disease populations have high rates of anxiety and depression, there
are several reasons why this is detrimental to the lives of these patients. Anxiety and depression
have been shown to have a significant association with disease symptoms like pain and dyspnea
severity 21. When controlling for physical ailments, the presence of anxiety and depression were

found to increase the cost of care by 45% in COPD patients 20. COPD patients with these
diagnoses are also more likely to have increased utilization rates and costs associated with their
care during their visit at the hospital 20. Along with an increased cost of care, the presence of
depression in a COPD population is associated with an 12% increase in COPD-related physician
visits, 2% higher number of annual hospitalizations, and 48% more COPD-related ER visits 24.
This same population is also more likely to have an increased length of stay at hospitals. Mental
health has also been shown to affect patients’ ability to self-manage disease 25 26. Although all of
these are important factors that pulmonologists need to keep in mind when treating their lung
disease patients, none of this matters if the patient isn’t being adequately treated for their mental
health. One study found that in COPD patients with depression, only 27-33% were being treated
for it 25. Anxiety also has been shown to affect a large portion of patients not being treated for it
27

.
Overall, although no studies have determined it to be so, based on the risks for depression

and anxiety for patients with similar lung diseases, NTM patients may have high risk of anxiety
and depression. NTM patients are mostly elderly, female, with many medications and symptoms,
all of which are risk factors for depression and anxiety. The importance of researching
depression and anxiety in this patient population goes beyond helping patients feel better.
Research suggests that depression and anxiety may impact treatment adherence, as suspected
with coronary artery disease patients 28. This is especially important since both CF and
bronchiectasis patients have shown low treatment adherence over the course of several months
29

. CF patients tend to report high treatment burden due to the intensive measures required to

take the medication, much like how involved NTM medication regimens are 26.

To help determine if patients experience affective disorder symptoms, providers and
researchers use screening tools. The most common screening tools for anxiety are the Anxiety
Inventory for Respiratory Disease (AIR) and the Generalized Anxiety Disorder Scale (GAD7). The most common screening tools for depression are the Hospital Anxiety and Depression
Scale (HADS) and Patient Health Questionnaire Scale (PHQ-9). Although there are two scales
that were specifically made for the elderly population; Geriatric Depression Scale (GDS-15) and
Geriatric Anxiety Scale (GAS-10), since some NTM patients are not elderly, using the geriatric
scales are not justified 30 31. This study will use the PHQ-8, a depression screening tool, and the
GAD-7, an anxiety screening tool. Both screening tools, similar to other tools of the same
purpose, have been shown to have high validity and reliability in screening for these two mental
health diseases 32 33. The PHQ-8 gives a maximum value of 24 and the GAD-7 gives a maximum
value of 21. A score greater than or equal to 10 is deemed diagnostic as seen from literature for
the PHQ-8 and GAD-7 34 32.
This thesis will determine if there is inadequate surveillance of mental health care from
Primary care physicians (PCP’s). Additionally, as explained in the abstract, this thesis will
determine if there is a need for Pulmonologists to screen for depression/anxiety in NTM patients.
The authors of one article, deemed the largest anxiety and depression screening to date for CF
patients, recommends yearly screenings for both disorders 35. Additionally, the US Preventative
Task Force recommends that anyone over the age of 60 years old should have regular screening
for depression. But this screening should be paired with an environment that can treat, diagnose,
and follow up with the patient 36 37. The process of deciding who will screen the patients may be
problematic since PCPs bear the greatest burden of diagnosing and treating mental health
disorders in their patients, but the nature of primary care practice (high patient loads, short office

visits, multiple diagnoses, etc.) may sometimes cause problems to fall through the cracks. Since
mental health has been shown to affect disease outcomes like treatment adherence and success,
all providers must make it a priority to discover what obstacles the patient may face that will
prevent clinical success.

Methods/Project Design:

Main study methods:

The study took place at the Oregon Health and Science University (OHSU) Hospital’s
Pulmonology Medicine clinic. The two attending physicians were Dr. Kevin Winthrop and Dr.
Luke Strnad. The consent and survey process took place at the clinic. Following consent, the
research coordinator (myself and other IDS staff) gave the patients two surveys; The PHQ-8, and
the GAD-7 scale. The original study was made to create a repository of NTM-positive patient
information for multiple studies. The biobank repository allows the Infectious Disease staff to
analyze and observe disease activity, quality of life, NTM module validity, and human specimen
immune response for our NTM population. Although this thesis is primarily a chart review of
cohort NTM patients, patient recruitment and screening will continue indefinitely, by both
myself and OHSU IDS staff.

Thesis project:

The data taken at enrollment was date of birth, ethnicity, gender, marital status, highest
education level, GAD-7 score, and PHQ-8 score. The screening scores were stored in OHSU’s
HIPAA approved research database, REDcap. Patient information in REDcap was paired with a
study ID. In order to connect the study ID with the patient’s name and MRN, a separate
password protected database was accessed.
During this chart review I looked into the patient's electronic medical records using Epic.
Two things were searched for in Epic about depression and anxiety; history of diagnosis and
psychotherapeutic medications. Since most of the patients do not maintain their primary care at
OHSU, their medical records were shared to the OHSU Epic system, Care Everywhere.
Diagnosis information was found in the “problems list”, “resolved problems list”, or “medical
history” list. Anything posted in these categories on Epic require a diagnosis, prior to display.
The presence of psychotherapeutic medications was found by going into the “Chart Review”
section of Epic and finding the day of enrollment. By opening the provider’s “Encounter
summary”, I was able to cross reference the list of medications they were taking with a list of the
most common depression and anxiety medications. This list included both generic and brand
name medications as shown from Table 1 and Table 2. The sources for this list include the FDA,
the Mayo clinic, WebMD, Healthyplace, and Healthline, with every medication on the list being
sourced from at least two places. For those with a diagnosis and a medication that was dualpurpose for anxiety or depression, I paired the medication intent with the diagnosis. For those
with a dual-purpose medication, but no diagnosis, both anxiety and depression were labeled as
the intent for the medication.

Table 1. List of Depression Medications Used in Analysis
Class type

Brand Name

Celexa *
Lexapro *
Selective Serotonin Reuptake Paxil, Pexeva *
Inhibitors (SSRIs)
Prozac
Luvox*
Zoloft *
Emsam *
Monoamine Oxidase Inhibitors Marplan *
(MAOIs)
Nardil *
Phenelzine *
Elavil, Endep, Levate
Asendin
Norpramin, Pertofrane *
Adapin, Silenor, Sinequan *
Tricyclic Antidepressants
Tofranil *
Anafranil *
Aventyl, Pamelor
Vivactil
Surmontil, Trimip, Tripramine
Ludimol
Desyrel*

Generic Name
Citalopram *
Escitalopram *
Paroxetine *
Fluoxetine *
Fluvoxamine*
Sertraline *
Selegiline *
Isocarboxzaid *
Parnate *
Tranylcypromine *
Amitriptyline
Amoxapine
Desipramine *
Doxepin *
Imipramine *
Clomipramine *
Nortriptyline
Protriptyline
Trimipramine
Maprotiline
Trazodone *
Nefazodone
Mirtazapine
Vilazodone
Vortioxetine

Remeron
Viibryd
Atypical Antidepressants
Trintellix, Brintellix
Wellbutrin, Wellbutrin,
Aplenzin, Forfivo XL, Budeprion
SR, Budeprion XL, Buproban,
Bupropion
Wellbutrin SR, Wellbutrin XR,
Zyban
Cymbalta *
Duloxetine *
Selective Serotonin and
Effexor, Effexor XR *
Venlafaxine *
Norepinephrine Reuptake
Pristiq, Khedezla
Desvenlafaxine
Inhibitors (SNRI)
Fetzima
Levomilnacipran
Medications with astrisk (*) can be used on both anxiety and depression

Table 2. List of Anxiety Medications Used in Analysis
Class type

Benzodiazepines

Anticonvulsants

Beta-Blockers

Antipsychotic

Brand Name
Xanax
Librium
Klonopin
Valium
Ativan
Serax
Depakote, Depakote ER
Neurontin
Lyrica
Tenormin
Corgard
Inderal, Betachron E-R,
InnoPran XL
Moban
Zyprexa
Seroquel
Risperdal

Generic Name
Alprazolam
Chlordiazepoxide
Clonazepam
Diazepam
Lorazepam
Oxazepam
Divalproex
Gabapentin
Pregabalin
Atenolol
Nadolol
Propranolol
Molindone
Olanzapine
Quetiapine
Risperidone

Once medication use and diagnosis data were extracted, the access dataset was converted
to a delimited comma-separated file and imported to Stata. Once in Stata the categorical marital
status was recorded to become a dichotomous variable. Ethnicity, a once categorical variable,
was also recorded to become dichotomous variable. For statistical analysis, a chi-square was
taken for both anxiety and depression, between positive screening scores and the presence of a
diagnosis or medication.

Results:

As shown in Table 3, the participants are mostly white (89%), with a partner (67%), and
have a variety of education levels. Although about fifty percent of the patient population don’t
have a college degree, the proportions between education levels listed are nearly the same
proportion between categories. The percentage of those with a high school diploma, college
degree, some college, and professional degrees are 29%, 25%, 26%, and 20% respectively. The
average age is 70 years old, which classifies the patient population as “old or elderly” 38. Another
important factor is that the participants were disproportionately female, with 78% being female
and 22% being male. The ethnicity, average age, and gender proportions in this study were
consistent with previous research done in Oregon, as listed in the Literature review section.
Finally, the average score for the GAD-7 and the PHQ-8 are 4.5 and 5 respectively.

Table 3. Demographics
N (%)
Anxiety Screening Score
Depression Screening Score
Highest Education Level
High school or less
Some college
Bachelor's degree
Professional or graduate degree
Race
White
Marital Status
In a relationship
Gender
Female
Age
Participants (n)

Mean (SD)
4.00 (4.00)
4.50 (5.09)

Range
(0-21)
(0-23)

61 (28.65)
55 (25.82)
70 (25.35)
43 (20.19)

(0, 1)
(0, 1)
(0,1)
(0, 1)

189 (88.73)

(0, 1)

142 (66.66)

(0, 1)

166 (77.93)

(0, 1)
(27-95)

70.02 (12.34)
213

As demonstrated in Table 4, the proportion of patients who screened positive on the
depression screening tool or anxiety screening tool were 20% and 14% respectively. Out of all
the patients, 32% had a depression diagnosis and 28% were taking medication for depression. On
the other hand, 34% had a diagnosis and 34% were taking medication for anxiety.
Table 4. Descriptive statistics of Anxiety and Depression
N (%)
Screened Positive:
Anxiety
30 (14.00)
Depression
42 (19.70)
Had diagnosis:
Anxiety
72 (33.80)
Depression
68 (31.92)
Took medication:
Took Anxiety Medication at enrollment
72 (33.80)
Took Depression Medication at enrollment
60 (28.17)

Table 5 demonstrates the difference in diagnosis and medication status between those
who screened positive and those who screened negative for anxiety and depression. Within those
who screened positive using the GAD-7, 43% had both a diagnosis and were taking medication,
17% had just a diagnosis. 20% had neither, and 20% were just taking medications. On the other
hand, of those who screened positive for the PHQ-8; 38% had both a diagnosis and were taking
medications, 14% had just a diagnosis, 2% were just taking medications, and 45% had neither.

Table 5: Comparing Those Who Screened Positive For Depression v.s. Anxiety
Mean
N (%)
Score
PHQ-8 >=10
Diagnosis and Medications
16 (38.10) 12.81
Just Diagnosis
6 (14.29) 15.17
Just Medications
1 (2.38)
10.00
Neither
19 (45.24) 14.00
GAD-7 >=10
Diagnosis and Medications
13 (43.33) 13.46
Just Diagnosis
5 (16.67) 13.20
Just Medications
6 (20.00) 15.67
Neither
6 (20.00) 15.17

Table 6 shows the Chi-square of screening results and prescription/diagnosis status. The
mean GAD-7 score for those who had a diagnosis and were prescribed medication were 5.71 and
6.06 respectively. On the other hand, the mean PHQ-8 score for those who had a diagnosis and
were prescribed medication were 7.05 and 6.3 respectively. The number of those who screened
positive on the PHQ-8 and had a diagnosis or had a depression medication prescription was 68
and 60 respectively. On the other hand, the number of those who screened positive on the GAD7 and had a diagnosis or had a depression medication prescription was 72 and 72 respectively.
The chi-square showed that there is a significant relationship between PHQ-8 results and the
presence of a diagnosis (p<0.05). Additionally, there was a significant relationship between the
PHQ-8 results and the presence of a prescribed depression medication (p<0.001). The chi-square
also showed that there is a significant relationship between GAD-7 results and the presence of a
diagnosis (p<0.001). Finally, there is a significant relationship GAD-7 results and the presence of
prescribed medication (p<0.001).

Table 6: Chi-square of Sreening Results versus Diagnosed & Perscribed
Medication
N (%)
Chi-Square
N
Screened Mean (SD)
P-value
Positive
PHQ-8
Perscribed Medication
60
17 (40.00) 6.30 (4.93)
0.000
Diagnosed
68
22 (52.38) 7.05 (5.53)
0.048
GAD-7
Perscribed Medication
72
19 (63.33) 6.06 (5.52)
0.000
Diagnosed
72
18 (60.00) 5.71 (5.17)
0.000

Discussion:

As seen from Table 4, a higher percentage of patients had a diagnosis or took medications
for anxiety, compared to depression. But a greater proportion screened positive for depression, as
opposed to anxiety. This suggests that patients were more likely to be depressed at enrollment.
The screening tool is useful for determining whether or not someone has depressive symptoms,
but is not absolutely diagnostic. There are several reasons why a greater portion have a
diagnosis and medications for anxiety. Firstly, feelings of anxiousness are a common
overarching symptom in chronic disease patients. Additionally, anxiety symptoms are
objectively easier to identify compared to depressive symptoms. Also, symptoms for depression
are often more subtle. Finally, because of the immediate connection to depression disorder and
the stigma that inherently goes with saying someone is “sad” or feeling depressed”, patients may
feel less inclined to voluntarily offer up information surrounding this topic. Whereas with
anxiety, expressing feelings of anxiousness or stress are more normalized, therefore a patient
might offer information relating to this more freely.

Additionally, a number of patients were given medications without a diagnosis for both
anxiety and depression. There are three possible reasons for this. Firstly, there could be fewer
depression medications that have dual purposes with other disorders compared to anxiety
medications. Secondly, anxiety symptoms are more generalizable to many other disorders, such
as Post-traumatic stress disorder, panic disorder, phobias, social anxiety disorder, and insomnia.
Someone might take the medication for a different anxiety disorder, other than general anxiety
disorder. Third, it’s possible that the after initial evaluation, the symptoms presented differently
for a different diagnosis than before 39. Someone could be diagnosed for anxiety, then years later
develop depression, but since the medication is often dual-purpose, they could use it for both.
Fourth, maybe providers are prescribing psychotherapeutic medications without a diagnosis.
Finally, patients may request that depression or anxiety not be listed as a diagnosis in their
medical file, for fear of stigma.
To break down Table 5 further, when looking into those who scored positive in the GAD7, 80% had either a diagnosis or took medications, while 20% had neither. For those who
screened positive on the PHQ-8, 56% had either a diagnosis or took medications, while 45% had
neither. A greater proportion of patients who scored positive for anxiety compared to depression,
already had a diagnosis or prescription compared to those within the same group who didn’t have
an either of those things. Whereas, a greater proportion of those who scored positive for
depression, compared to anxiety, have unrecognized depression with no intervention.
For those with seemingly unrecognized symptomology, there are several possible reasons
for this. First, their PCP might not be regularly screening them. Second, the patient could have
requested the information be removed from their medical record. Third, there might be records
missing from the Care Everywhere and EPIC system from other institutions.

Besides those with no clinical history, the other group who screened positive are those
with medications or a diagnosis. It’s important to note that EPIC does not provide information on
other forms of therapy like talk therapy, Yoga, exercise, art therapy, or music therapy. It’s
possible that those with just a diagnosis declined taking medication, were using alternative
therapy styles, or did nothing at all. For those who were taking medications without a diagnosis,
since the medical records available during chart review were incomplete, the diagnosis may be
missing in other medical record files. Additionally, the medication that the patient used at time of
diagnosis needed modifications or supplemental therapies to do alongside the pharmaceutical.
Finally, it’s possible the patient wasn’t taking the medication as intended so the desired effects
were not presenting. Overall, those who screened positive and had a diagnosis or prescription
psychotherapeutic need follow up for re-evaluation of treatment.
Table 6 demonstrated that the screening results for both anxiety and depression were
dependent on the presence of a diagnosis or medication prescription. This shows that follow up
with patients who have pre-existing symptoms is important for future mental health
management.

Limitations:

There are several limitations to this study. First, when looking into the medications
prescribed to patients, it was found that most of the time neither Care-everywhere, OHSU Epic
system, or the Encounter summary from the provider would describe what the medication was
used for. This is a limit because the data may overestimate those who took one type of

psychotherapeutic medication over the other. While several charts showed indications attached to
medications, it was a common trend for the indications to be absent. This also could have been
done via the patients request for privacy. Ultimately it is better practice to always provide
indications for medications to facilitate continuity of care and viability of these data for future
research.
Second, the time of diagnosis was not listed in the patient’s problem list, resolved
problem list, or medical history list. Marking when the diagnosis or start of symptoms appeared
for the patient not only can be helpful for providers, but also researchers who want to look into
treatment success for mental health interventions. This is a limit to the study because the chart
review process sometimes happened years after the enrollment date. Essentially, some patients
could have been diagnosed after the screening date.
Third, it’s possible that patients weren’t taking their medications due to adverse side
effects, complications with other medications, or polypharmacy from multiple illnesses that
make keeping track difficult. Although there is no for sure way to determine if patients are taking
their medications, this needs to be considered when discussing limitations.
Fourth, the Epic system does not list other forms of treatment that the patient might
access, like talk therapy, yoga, meditation, and exercise. All of these are valid forms of treatment
for anxiety or depression but can only be accessed through the use of survey, not chart review.
This is a limitation because the study maybe underestimating the proportion of patients receiving
treatment.
Finally, the usage of the PHQ-8 instead of PHQ-9 is potentially problematic. Most
studies looking at depression use the PHQ-9 over the PHQ-8, therefore there is more research on
the cutoff for a positive screening score in the PHQ-9. The PHQ-9, compared to PHQ-8, includes

a question about suicidal ideations. The decision to use the PHQ-8 within the Infectious Disease
lab was originally made because this lab doesn’t have the ability to adequately follow up with
patients if they indicate that they have suicidal ideations, as per state law.

Generalizability of results:

The demographic information gained from this study like average age and gender were
similar to other studies in areas such as South Korea, Hawaii, the United States mainland, and
Zambia. Overall, the average age of studied NTM populations seems to be between the ages of
60 and 70 years old. Additionally, in all of these locations women showed a higher prevalence,
compared to men, for NTM diagnosis 40 41 42. This study and other Oregon NTM studies have a
higher proportion of patients that are white, compared to other races. When looking at an article
that specifically studied the epidemiology of the NTM in the United States, excluding Hawaii,
Puerto Rico, and Alaska, the proportion of white participants was 70% compared to the 88%
found from this study 43. Oregon, compared to the rest of the United States, is very white which
explains the result differences in ethnicity. Overall, these results are most generalizable to the
Oregon NTM population and less so for the rest of the United States due to the lack of racial
diversity.

Possible Bias:

The most apparent bias from this study is convenience selection bias and extraction
researcher bias. This researcher extraction bias was mitigated by creating clear extraction

procedures in regards where to find the data and by creating a set list of medications to cross
reference. With regards to the selection bias, the patients needed to be recruited to OHSU from a
different pulmonologist. There are several factors that could lead a patient to refuse the referral
to OHSU such as difficulty reaching the location, cost, and availability.
Other possible biases that could have arose were procedural bias, measurement bias, and
response bias. Procedural bias is possible because the questionnaire was filled out after the
Pulmonology visit and right before the patient went in for a blood draw. Therefore, it is possible
that they were rushing as they filled out the questionnaires. Measurement bias is possible
because mental health is a personal topic that many Americans feel shame over. Since the
questions are all about mental health, it’s possible that patients underreported how often they felt
those symptoms. Therefore, as said before, the current results could be underestimations of the
true burden of mental health in the NTM populations. Although Response bias is always a
possibility with surveys, this was mitigated by stating, during the consent process, the purpose of
the experiment, rather than what we expect from the experiment.

Conclusion:
The prevalence, incidence, and impact of anxiety and depression in the NTM patient
population has yet to be researched. Through this project, the prevalence of anxiety and
depression, as well as the comorbidity of both was determined for one group of patients. With
these data, I found that within this patient population, a higher proportion had a diagnosis or took
a medication for anxiety, compared to depression. A higher proportion had a positive screening
score for depression, compared to anxiety. The chi-square for both anxiety and depression
showed a significant relationship between screening results and the presence of a diagnosis or

prescription of medication. Overall, this patient population has mostly unrecognized anxiety and
unresolved symptomatology in both disorders. Therefore, patients who screen positive need
follow up for either a first-time diagnosis and treatment plan, or re-evaluation and additional
support.
My recommendation from these results would be to screen all NTM patients every six
months, which is the time period between most visits in the Infectious Disease clinic at OHSU. I
also recommend collaborative care for patients suffering with mental illness, between the
pulmonologist and primary care provider, and in some cases, with a mental health professional.
Direct follow-up with either the patient or PCP is important once a patient screens positive for
either of these diseases. Without follow up, the patient may continue living with unresolved
symptoms. These very same symptoms are known to affect health outcomes, treatment
adherence, and symptom severity in other lung disease populations, as described in the literature
review.
In conclusion, more research on mental illness within this population needs to be done.
As more cases of NTM are discovered, the Infectious Disease research team will continue to
monitor these aliments in NTM patients, and hopefully provide appropriate referrals for effective
treatments. For future projects the IDS team will look at screening scores over the life course of
treatment plans, treatment adherence, and NTM symptomatology, in order to better understand
mental health burden in this population.
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